{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:56:42Z","timestamp":1788278202492,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate anifrolumab\u2019s ability to treat cutaneous and extracutaneous manifestations of dermatomyositis (DM) refractory to conventional systemic therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed the records of patients with adult-onset DM managed at the Cutaneous Autoimmune Connective Tissue Disease Clinic in the Department of Dermatology at Johns Hopkins Hospital who received 300\u2009mg infusions of anifrolumab every 4 weeks between April and August 2024 for refractory disease. Data on demographics, disease severity, lab findings, Dermatology Life Quality Index (DLQI) and treatment details were collected. Cutaneous improvement was evaluated using the Cutaneous Dermatomyositis Disease Area and Severity Index-Activity (CDASI-A), while extracutaneous symptoms were assessed through lab results, physical exams and subjective reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four patients were identified. Clinical responses were assessed after three infusions for patients 1 and 3 and two infusions for patients 2 and 4. All patients showed improvement in cutaneous disease, with a median (range) CDASI-A reduction of 12 points or 49.4% (5\u201321; 26.9\u201377.8%). Patients 1\u20133 also experienced improvement in extracutaneous symptoms, including arthralgia\/synovitis, dysphagia, muscle strength and creatine kinase levels. Patients 1 and 4 tapered or discontinued systemic therapies including steroid. Pre-anifrolumab DLQI data, available for two patients, showed post-treatment improvement. No anifrolumab-related adverse effects were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case series is the first to demonstrate anifrolumab\u2019s potential to treat refractory extracutaneous manifestations of adult-onset DM, facilitate prednisone tapering and discontinue systemic therapies. These findings provide new evidence that systemic blockade of type I interferon can manage treatment-resistant multi-organ DM manifestations, including skin, joint and muscle involvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf388","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T13:58:23Z","timestamp":1752501503000},"page":"6354-6358","source":"Crossref","is-referenced-by-count":9,"title":["Improvement of recalcitrant multisystem disease in dermatomyositis with anifrolumab: a case series"],"prefix":"10.1093","volume":"64","author":[{"given":"Saloni","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Jeurling","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8030-9504","authenticated-orcid":false,"given":"Jemima","family":"Albayda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4749-870X","authenticated-orcid":false,"given":"Eleni","family":"Tiniakou","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7883-0798","authenticated-orcid":false,"given":"Jun","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"2026072404062651400_keaf388-B1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2026072404062651400_keaf388-B2","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.3390\/biomedicines11112904","article-title":"Anifrolumab for moderate and severe muco-cutaneous lupus erythematosus: a monocentric experience and review of the current literature","volume":"11","author":"Paolino","year":"2023","journal-title":"Biomedicines"},{"key":"2026072404062651400_keaf388-B3","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","article-title":"Interferon \u03b2 is associated with type 1 interferon-inducible gene expression in dermatomyositis","volume":"70","author":"Liao","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026072404062651400_keaf388-B4","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"2026072404062651400_keaf388-B5","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026072404062651400_keaf388-B6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","article-title":"Efficacy, safety, and target engagement of dazukibart, an IFN\u03b2 specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Fiorentino","year":"2025","journal-title":"Lancet"},{"key":"2026072404062651400_keaf388-B7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaad.2024.07.1491","article-title":"Anifrolumab in recalcitrant cutaneous dermatomyositis: a multicenter retrospective cohort study","volume":"91","author":"Shaw","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026072404062651400_keaf388-B8","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/ced\/llae476","article-title":"Anifrolumab use in refractory dermatomyositis: a case report and literature review","volume":"50","author":"Claudio-Oliva","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026072404062651400_keaf388-B9","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/bjd\/ljaf064","article-title":"Improvement in dermatomyositis-associated muscle disease with anifrolumab","volume":"192","author":"Shayegan","year":"2025","journal-title":"Br J Dermatol"},{"key":"2026072404062651400_keaf388-B10","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2026072404062651400_keaf388-B11","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026072404062651400_keaf388-B12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"2026072404062651400_keaf388-B13","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2026072404062651400_keaf388-B14","doi-asserted-by":"crossref","first-page":"A1194","DOI":"10.1016\/j.chest.2021.07.1097","article-title":"Use of anti-interferon beta monoloncal antibody for case of MDA-5 dermatomyositis and associated interstitial lung disease","volume":"160","author":"Nasim","year":"2021","journal-title":"Chest"},{"key":"2026072404062651400_keaf388-B15","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","article-title":"MDA5+ dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-\u03ba transcript","volume":"140","author":"Cassius","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2026072404062651400_keaf388-B16","doi-asserted-by":"crossref","first-page":"e139558","DOI":"10.1172\/jci.insight.139558","article-title":"IL18-containing 5-gene signature distinguishes histologically identical dermatomyositis and lupus erythematosus skin lesions","volume":"5","author":"Tsoi","year":"2020","journal-title":"JCI Insight"},{"key":"2026072404062651400_keaf388-B17","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"2026072404062651400_keaf388-B18","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026072404062651400_keaf388-B19","doi-asserted-by":"crossref","first-page":"103420","DOI":"10.1016\/j.autrev.2023.103420","article-title":"IFN-\u03b3: an overlooked cytokine in dermatomyositis with anti-MDA5 antibodies","volume":"22","author":"Thuner","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026072404062651400_keaf388-B20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf388\/63769774\/keaf388.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/12\/6354\/63769774\/keaf388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/12\/6354\/63769774\/keaf388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:06:35Z","timestamp":1784880395000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/12\/6354\/8202930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf388","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,7,15]]}}}